These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 31375513)
1. Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Lazzari L; Corti G; Picco G; Isella C; Montone M; Arcella P; Durinikova E; Zanella ER; Novara L; Barbosa F; Cassingena A; Cancelliere C; Medico E; Sartore-Bianchi A; Siena S; Garnett MJ; Bertotti A; Trusolino L; Di Nicolantonio F; Linnebacher M; Bardelli A; Arena S Clin Cancer Res; 2019 Oct; 25(20):6243-6259. PubMed ID: 31375513 [TBL] [Abstract][Full Text] [Related]
2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
3. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Lieb S; Blaha-Ostermann S; Kamper E; Rippka J; Schwarz C; Ehrenhöfer-Wölfer K; Schlattl A; Wernitznig A; Lipp JJ; Nagasaka K; van der Lelij P; Bader G; Koi M; Goel A; Neumüller RA; Peters JM; Kraut N; Pearson MA; Petronczki M; Wöhrle S Elife; 2019 Mar; 8():. PubMed ID: 30910006 [TBL] [Abstract][Full Text] [Related]
4. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Picco G; Cattaneo CM; van Vliet EJ; Crisafulli G; Rospo G; Consonni S; Vieira SF; Rodríguez IS; Cancelliere C; Banerjee R; Schipper LJ; Oddo D; Dijkstra KK; Cinatl J; Michaelis M; Yang F; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Arena S; Voest EE; Bardelli A; Garnett MJ; Cancer Discov; 2021 Aug; 11(8):1923-1937. PubMed ID: 33837064 [TBL] [Abstract][Full Text] [Related]
6. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170 [TBL] [Abstract][Full Text] [Related]
7. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152 [TBL] [Abstract][Full Text] [Related]
8. Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer. Hao S; Tong J; Jha A; Risnik D; Lizardo D; Lu X; Goel A; Opresko PL; Yu J; Zhang L Proc Natl Acad Sci U S A; 2022 Dec; 119(51):e2211775119. PubMed ID: 36508676 [TBL] [Abstract][Full Text] [Related]
9. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343 [TBL] [Abstract][Full Text] [Related]
10. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. De Cuyper A; Van Den Eynde M; Machiels JP Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076 [TBL] [Abstract][Full Text] [Related]
11. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374 [TBL] [Abstract][Full Text] [Related]
12. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Corti G; Bartolini A; Crisafulli G; Novara L; Rospo G; Montone M; Negrino C; Mussolin B; Buscarino M; Isella C; Barault L; Siravegna G; Siena S; Marsoni S; Di Nicolantonio F; Medico E; Bardelli A Clin Colorectal Cancer; 2019 Jun; 18(2):91-101.e3. PubMed ID: 30981604 [TBL] [Abstract][Full Text] [Related]
14. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271 [TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of cell lines from chromosomal instable colorectal cancer. Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089 [TBL] [Abstract][Full Text] [Related]
16. A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. Corso S; Isella C; Bellomo SE; Apicella M; Durando S; Migliore C; Ughetto S; D'Errico L; Menegon S; Moya-Rull D; Cargnelutti M; Capelôa T; Conticelli D; Giordano J; Venesio T; Balsamo A; Marchiò C; Degiuli M; Reddavid R; Fumagalli U; De Pascale S; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Pietrantonio F; Morano F; Siena S; Sartore-Bianchi A; Bencivenga M; Mengardo V; Rosati R; Marrelli D; Morgagni P; Rausei S; Pallabazzer G; De Simone M; Ribero D; Marsoni S; Sottile A; Medico E; Cassoni P; Sapino A; Pectasides E; Thorner AR; Nag A; Drinan SD; Wollison BM; Bass AJ; Giordano S Cancer Res; 2019 Nov; 79(22):5884-5896. PubMed ID: 31585941 [TBL] [Abstract][Full Text] [Related]
17. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Wasserman I; Lee LH; Ogino S; Marco MR; Wu C; Chen X; Datta J; Sadot E; Szeglin B; Guillem JG; Paty PB; Weiser MR; Nash GM; Saltz L; Barlas A; Manova-Todorova K; Uppada SPB; Elghouayel AE; Ntiamoah P; Glickman JN; Hamada T; Kosumi K; Inamura K; Chan AT; Nishihara R; Cercek A; Ganesh K; Kemeny NE; Dhawan P; Yaeger R; Sawyers CL; Garcia-Aguilar J; Giannakis M; Shia J; Smith JJ Clin Cancer Res; 2019 Mar; 25(6):1948-1956. PubMed ID: 30587545 [TBL] [Abstract][Full Text] [Related]
18. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727 [TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research. Suto H; Funakoshi Y; Nagatani Y; Imamura Y; Toyoda M; Kiyota N; Matsumoto H; Tanaka S; Takai R; Hasegawa H; Yamashita K; Matsuda T; Kakeji Y; Minami H J Cancer Res Ther; 2021; 17(6):1358-1369. PubMed ID: 34916366 [TBL] [Abstract][Full Text] [Related]
20. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]